Examination of the effect of Neisseria outer membrane vesicles on T cell responses to recombinant vaccine antigens
Lead Research Organisation:
University of Manchester
Department Name: School of Biological Sciences
Abstract
Outer membrane vesicles (OMVs) are currently attracting considerable interest as potential components in vaccines against bacteria. OMVs consist of a complex mixture of lipopolysaccharide (LPS), proteins, capsular oligosaccharides and other components. They are known to stimulate an adjuvant-like effect on added recombinant protein antigens, but the basis for this effect is poorly understood. A robust and protective IgG antibody response requires CD4+ T-cell help to antigen-specific B cells. This project is focussed specifically on an evaluation of the influence of OMV composition on T cell responses to vaccine antigens. It will combine protein design and engineering with in vitro and in vivo methods for the study of antigen-specific T cell proliferation. The project would particularly suit a student with a background in Biochemistry or Biological Chemistry, who would like to apply their skills to an exciting field of current development within vaccinology. The project will use a Design-Build-Test cycle approach, employing molecular graphics and computational tools to design engineered antigens, which will then be expressed, purified and tested using a range of immunological assays. A major attraction of the project is the collaboration with the major pharmaceutical company GSK, one of the world's leading developers and manufacturers of vaccines. This is an exceptional opportunity for a student to develop their skills in an exciting area of biomedicine and commercial vaccine development.
People |
ORCID iD |
Jeremy Paul Derrick (Primary Supervisor) | |
Jakub Palinski (Student) |
Studentship Projects
Project Reference | Relationship | Related To | Start | End | Student Name |
---|---|---|---|---|---|
MR/W007428/1 | 01/10/2022 | 30/09/2028 | |||
2899745 | Studentship | MR/W007428/1 | 01/10/2023 | 30/09/2027 | Jakub Palinski |